- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 209/44 - Iso-indoles; Hydrogenated iso-indoles
Patent holdings for IPC class C07D 209/44
Total number of patents in this class: 506
10-year publication summary
|
26
|
40
|
27
|
43
|
32
|
36
|
29
|
38
|
26
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Abbvie Inc. | 1782 |
13 |
| Neophore Limited | 17 |
13 |
| AstraZeneca AB | 2958 |
10 |
| Achillion Pharmaceuticals, Inc. | 168 |
10 |
| Cognition Therapeutics, Inc. | 37 |
8 |
| Taisho Pharmaceutical Co., Ltd. | 862 |
8 |
| F. Hoffmann-La Roche AG | 7942 |
7 |
| Astex Therapeutics Limited | 250 |
7 |
| Orion Corporation | 595 |
7 |
| VALO Health, Inc. | 168 |
7 |
| The General Hospital Corporation | 4650 |
6 |
| Astellas Pharma Inc. | 1125 |
6 |
| The Broad Institute, Inc. | 1709 |
6 |
| Mitsubishi Tanabe Pharma Corporation | 576 |
6 |
| Nerviano Medical Sciences S.r.l. | 256 |
6 |
| Massachusetts Institute of Technology | 9913 |
5 |
| Jiangsu Hengrui Medicine Co., Ltd. | 760 |
5 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 627 |
5 |
| The University Court of the University of Aberdeen | 122 |
5 |
| Bristol-myers Squibb Company | 4863 |
4 |
| Other owners | 362 |